Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$1.41B |
| 2 |
ExxonMobil
XOM
|
+$937M |
| 3 |
Eli Lilly
LLY
|
+$875M |
| 4 |
Tesla
TSLA
|
+$749M |
| 5 |
GE Aerospace
GE
|
+$740M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$1.99B |
| 2 |
Deutsche Bank
DB
|
+$1.49B |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$1.12B |
| 4 |
Broadcom
AVGO
|
+$1.12B |
| 5 |
Amgen
AMGN
|
+$1.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.51% |
| 2 | Healthcare | 16.3% |
| 3 | Consumer Discretionary | 11.31% |
| 4 | Industrials | 10.9% |
| 5 | Financials | 9.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWT
376
DELISTED
Stanley Black & Decker, Inc.
SWT
| $24.4M | 0.01% |
362,661
-760,738
| -68% | -$59.4M |
|
377
AppFolio
APPF
$6.96B
| $24.3M | 0.01% |
267,626
-275,214
| -51% | -$27.7M |
|
378
ePlus
PLUS
$2.31B
| $24.2M | 0.01% |
454,900
+150,100
| +49% | +$8.4M |
|
|
ESGR
379
DELISTED
Enstar Group
ESGR
| $24M | 0.01% |
112,000
| – | – |
|
380
Douglas Elliman
DOUG
$187M
| $23M | 0.01% |
5,040,000
-422,497
| -8% | -$2.34M |
|
381
Lands' End
LE
$396M
| $22.3M | 0.01% |
2,100,000
| – | – |
|
|
JOAN
382
DELISTED
JOANN, Inc. Common Stock
JOAN
| $21.2M | 0.01% |
2,729,250
| – | – |
|
383
PLAYSTUDIOS Inc
MYPS
$69.1M
| $19.3M | 0.01% |
4,500,000
| – | – |
|
|
PETQ
384
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $18.7M | 0.01% |
1,115,100
+63,742
| +6% | +$1.17M |
|
385
VTEX
VTEX
$645M
| $18.2M | 0.01% |
5,907,296
+1,777,647
| +43% | +$8.58M |
|
386
Trupanion
TRUP
$1.33B
| $18.1M | 0.01% |
300,000
| – | – |
|
387
Cognex
CGNX
$10.3B
| $16.4M | 0.01% |
386,600
| – | – |
|
388
StepStone Group
STEP
$4.06B
| $16.2M | 0.01% |
623,800
+267,200
| +75% | +$7.27M |
|
389
Alcoa
AA
$13.5B
| $16M | 0.01% |
350,000
| – | – |
|
390
Installed Building Products
IBP
$6.53B
| $15.7M | ﹤0.01% |
189,361
| – | – |
|
|
AZEK
391
DELISTED
The AZEK Co
AZEK
| $15.4M | ﹤0.01% |
918,800
| – | – |
|
392
Adient
ADNT
$1.48B
| $14.9M | ﹤0.01% |
501,300
+86,850
| +21% | +$2.92M |
|
|
CVE.WS
393
DELISTED
Cenovus Energy Inc Warrants
CVE.WS
| $14.8M | ﹤0.01% |
1,066,345
| – | – |
|
394
Itaú Unibanco
ITUB
$81.3B
| $10.1M | ﹤0.01% |
+2,684,305
| New | +$11.9M |
|
395
LivePerson
LPSN
$35.4M
| $8.84M | ﹤0.01% |
41,674
+19,113
| +85% | +$5.38M |
|
396
Health Catalyst
HCAT
$138M
| $8.24M | ﹤0.01% |
568,785
-2,823,215
| -83% | -$48.1M |
|
397
NVIDIA
NVDA
$5.45T
| $7.33M | ﹤0.01% |
483,350
| – | – |
|
398
Marvell Technology
MRVL
$204B
| $7.12M | ﹤0.01% |
163,608
| – | – |
|
399
Toast
TOST
$19.9B
| $6.31M | ﹤0.01% |
487,305
| – | – |
|
|
VSXY
400
Victoria's Secret
VSXY
$7.3B
| $5.88M | ﹤0.01% |
210,400
+44,700
| +27% | +$1.94M |
|
Similar funds
Capital Research Global Investors's Q2 2022 Portfolio in Review
As of Q2 2022, Capital Research Global Investors held 461 positions worth $321B, down 21% from $405B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Capital Research Global Investors withdrew a net $12.2B in Q2 2022, closing 38 positions and reducing 158 holdings. Its most notable exit was Deutsche Bank, an estimated $1.49B position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Capital Research Global Investors opened a new position in Eli Lilly worth $945M.
- Capital Research Global Investors's largest Q2 2022 buy was Eli Lilly: 2,914,107 shares worth $945M.
- Capital Research Global Investors added most to AbbVie in Q2 2022, an estimated $1.41B increase.
- Capital Research Global Investors's biggest Q2 2022 reduction was JPMorgan Chase, cutting an estimated $1.99B.
- Capital Research Global Investors fully exited Deutsche Bank in Q2 2022, selling an estimated $1.49B.
- Capital Research Global Investors's ten largest holdings make up 29% of its $321B portfolio in Q2 2022.
- Capital Research Global Investors opened 21 new positions and closed 38 in Q2 2022.
- Capital Research Global Investors's portfolio value fell 21% quarter-over-quarter to $321B.
Based on Capital Research Global Investors's 13F filing for Q2 2022, filed 15 Aug 2022.